The Biggest M&A Announcements Of 2023 Show Deals Are Getting Bigger
Executive Summary
M&A activity in 2023 began with March’s $43bn mega-deal for Seagen, but only one eight-figure takeout has occurred since. Still, the values are higher overall than seen in 2022 and might indicate a gradual return to larger deals.
You may also be interested in...
Roche Makes Play For Bowel Disease Leadership With $7.1bn Roivant Deal
The Swiss pharma company has followed Merck & Co. and Sanofi by buying into the TL1A-inhibitor class, with pharma chief Teresa Graham confident RVT-3101 could be its next best-in-class blockbuster
Slow Q3 For Biopharma M&A Boosted By Biogen/Reata
Biogen’s acquisition of Reata lifted the third quarter’s M&A value above $13bn, but data from Evaluate show that acquisition activity cratered in both August and September.
BMS Looks To Expand Its Oncology Reach With Mirati Buyout
Bristol Myers Squibb will add Krazati to its oncology portfolio by buying Mirati Therapeutics in a deal worth up to $5.8bn, but needs to smooth out the so-far bumpy progress of the KRAS-targeting agent and achieve success in immunotherapy combinations.